Tuesday, July 9, 2024

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Awarded Final Judgment, Confirmation of $3M-Plus Arbitration Award

 FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that the United States District Court for the Eastern District of Pennsylvania ruled in favor of FSD Pharma and is granted its motion for entry of judgment against Dr. Raza Bokhari, the company’s former CEO. The decision awards FSD Pharma several awards, including $147,301.04 plus interest at a rate of 4% per annum from Nov. 9, 2022, until the date the judgment is satisfied; C$31,912.55 plus interest at a rate of 4% per annum from Nov. 9, 2022, until the date the judgment is satisfied; C$15,000 plus interest at a rate of 4% per annum from March 1, 2023, until the date the judgment is satisfied; and C$2,814,229.15 plus interest at a rate of 6% per annum from May 7, 2023, until the date the judgment is satisfied. The judgment results from action taken by Bokhari after FSD’s board of directors terminated him. “After years of litigation and an eight-day evidentiary hearing, the arbitrator ruled against Dr. Raza Bokhari and issued three awards against Dr. Raza Bokhari in favor of FSD, including an award for damages and awards for FSD’s fees and costs incurred in the arbitration,” stated the press release. “FSD will pursue all means possible to collect from Dr. Raza Bokhari, current chairman and CEO of Medicus Pharma Ltd.”

To view the full order, view https://ibn.fm/u0yvx

To view the full press release, visit https://ibn.fm/HYojF

About FSD Pharma Inc.

FSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (“Lucid-MS”). Lucid-MS is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. FSD Pharma invented unbuzzd(TM) and spun out its OTC version to Celly Nutrition, a company led by industry veterans. FSD retains ownership of 25.71% of Celly Nutrition Corp. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd until payments to FSD Pharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, FSD Pharma retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. FSD Pharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical/medical uses. FSD Pharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property. For more information about the company, please visit www.FSDPharma.com.

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN

No comments: